Search
 
NEWS
 

FDA Approval Sought for Talquetamab for the Treatment of R/R Multiple Myeloma - Targeted Oncology

 
 
Results from MonumenTAL-1 presented during the 2022 ASH annual Meeting have led to the submission of a biologics license application for talquetamab. - READ MORE
By Targeted Oncology
Tue, 13 Dec 2022 20:05:00 GMT
 
PREVIOUS NEXT
In R/R CLL, Zanubrutinib Offers 35% Improved PFS Over Ibrutinib; Edge Greater for Higher-Risk Patients - AJMC.com Managed Markets Network
Perspective | Toys R Us may have grown up, but the pandemic is fueling its rebirth - The Washington Post
Alexander R. Caron | News, Sports, Jobs - Nashua Telegraph
Trinity Life Sciences Announces the Appointment of Paul R. Lucchese as General Counsel - Business Wire
Phillips Evaluates Second-Line Therapy Options for R/R DLBCL - Targeted Oncology
Trenton R-9 Board of Education announces meeting results from Tuesday, December 13, 2022 - kttn
The New Honda Civic Type R Is Going Racing in 2023 - Car and Driver
An Introduction To Using R For SEO - Search Engine Journal
Tagged: #FDA #Approval #Sought #Talquetamab #Treatment #Multiple #Myeloma #Targeted #Oncology
ADD COMMENT
Topic
Name
5+8 =